» Articles » PMID: 28577585

Advancing Personalized Medicine: Application of a Novel Statistical Method to Identify Treatment Moderators in the Coordinated Anxiety Learning and Management Study

Overview
Journal Behav Ther
Publisher Elsevier
Date 2017 Jun 5
PMID 28577585
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

There has been increasing recognition of the value of personalized medicine where the most effective treatment is selected based on individual characteristics. This study used a new method to identify a composite moderator of response to evidence-based anxiety treatment (CALM) compared to Usual Care. Eight hundred seventy-six patients diagnosed with one or multiple anxiety disorders were assigned to CALM or Usual Care. Using the method proposed by Kraemer (2013), 35 possible moderators were examined for individual effect sizes then entered into a forward-stepwise regression model predicting differential treatment response. K-fold cross validation was used to identify the number of variables to include in the final moderator. Ten variables were selected for a final composite moderator. The composite moderator effect size (r = .20) was twice as large as the strongest individual moderator effect size (r = .10). Although on average patients benefitted more from CALM, 19% of patients had equal or greater treatment response in Usual Care. The effect size for the CALM intervention increased from d = .34 to d = .54 when accounting for the moderator. Findings support the utility of composite moderators. Results were used to develop a program that allows mental health professionals to prescribe treatment for anxiety based on baseline characteristics (http://anxiety.psych.ucla.edu/treatmatch.html).

Citing Articles

Identifying subgroups with differential response to CBASP versus Escitalopram during the first eight weeks of treatment in outpatients with persistent depressive disorder.

Serbanescu I, Schramm E, Walter H, Schnell K, Zobel I, Drost S Eur Arch Psychiatry Clin Neurosci. 2023; 274(3):723-737.

PMID: 37606728 PMC: 10995028. DOI: 10.1007/s00406-023-01672-0.


Building on the past 50 years, not starting over: A balanced interpretation of meta-analyses, reviews, and commentaries on treatments for suicide and self-injury.

Kleiman E, Bentley K, Glenn C, Liu R, Rizvi S Gen Hosp Psychiatry. 2021; 74:18-21.

PMID: 34800775 PMC: 11290550. DOI: 10.1016/j.genhosppsych.2021.11.002.


Internet-delivered cognitive behavioral therapy for youth with functional abdominal pain: a randomized clinical trial testing differential efficacy by patient subgroup.

Walker L, Stone A, Han G, Garber J, Bruehl S, Smith C Pain. 2021; 162(12):2945-2955.

PMID: 34793406 PMC: 8602868. DOI: 10.1097/j.pain.0000000000002288.


Predictive approaches to heterogeneous treatment effects: a scoping review.

Rekkas A, Paulus J, Raman G, Wong J, Steyerberg E, Rijnbeek P BMC Med Res Methodol. 2020; 20(1):264.

PMID: 33096986 PMC: 7585220. DOI: 10.1186/s12874-020-01145-1.


Psychotherapy or medication for depression? Using individual symptom meta-analyses to derive a Symptom-Oriented Therapy (SOrT) metric for a personalised psychiatry.

Kappelmann N, Rein M, Fietz J, Mayberg H, Craighead W, Dunlop B BMC Med. 2020; 18(1):170.

PMID: 32498707 PMC: 7273646. DOI: 10.1186/s12916-020-01623-9.


References
1.
Stein M, Roy-Byrne P, Craske M, Campbell-Sills L, Lang A, Golinelli D . Quality of and patient satisfaction with primary health care for anxiety disorders. J Clin Psychiatry. 2011; 72(7):970-6. PMC: 3111814. DOI: 10.4088/JCP.09m05626blu. View

2.
Kraemer H . Discovering, comparing, and combining moderators of treatment on outcome after randomized clinical trials: a parametric approach. Stat Med. 2013; 32(11):1964-73. DOI: 10.1002/sim.5734. View

3.
Kroenke K, Spitzer R, Williams J . The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001; 16(9):606-13. PMC: 1495268. DOI: 10.1046/j.1525-1497.2001.016009606.x. View

4.
Davidson J, Kudler H, Saunders W, Erickson L, Smith R, STEIN R . Predicting response to amitriptyline in posttraumatic stress disorder. Am J Psychiatry. 1993; 150(7):1024-9. DOI: 10.1176/ajp.150.7.1024. View

5.
Ackerman D, Greenland S, Bystritsky A, Morgenstern H, Katz R . Predictors of treatment response in obsessive-compulsive disorder: multivariate analyses from a multicenter trial of clomipramine. J Clin Psychopharmacol. 1994; 14(4):247-54. View